Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Part A Inclusion Criteria~To be included in the study the patient must:~* Have given written informed consent to participate~* Male~* Be aged between 18 and 30 years at the time of first study appointment~* BMI \<30~* Deemed healthy to partake in the study at the discretion of the investigator~Exclusion Criteria~The presence of any of the following will preclude patient inclusion:~* Less than 18 years old, \>30 years old~* BMI \>30~* On regular medications~* Known allergy to medications~* History of psychiatric, chronic cardiac / respiratory / renal disease~* Known diagnosis of diabetes~* Habitual smoker~* Screening heart rate of less than 60 beats per minute~* Screening heart rate of greater than 100 beats per minute~* Screening blood pressure of less than 100mmHg systolic and/or 55mmHg diastolic~* Any concomitant condition or circumstance that, at the discretion of the investigator, may affect the participant's ability to complete the study~* Current participation in another interventional research study~Part B Inclusion Criteria~To be included in the study the patient must:~* Have given written informed consent to participate~* Male~* Be aged over 18 years at the time of first study appointment~* Possess one of the following - known diagnosis of diabetes, known diagnosis of hypertension, obesity (BMI\>30), aged \>65~* Deemed healthy to partake in the study at the discretion of the investigator~Exclusion Criteria~The presence of any of the following will preclude patient inclusion:~* Less than 18 years old~* On regular medications that are contraindicated for co-use with the study drugs~* Known allergy to medications~* Screening heart rate of less than 60 beats per minute~* Screening heart rate of greater than 100 beats per minute~* Screening blood pressure of less than 100mmHg systolic and/or 55mmHg diastolic~* Any concomitant condition or circumstance that, at the discretion of the investigator, may affect the participant's ability to complete the study~* Current participation in another interventional research study~Part C Inclusion Criteria~To be included in the study the patient must:~* Have given written informed consent to participate~* Male~* Be aged over 18 years at the time of first study appointment~* Clinical diagnosis of autonomic dysfunction~* BMI\<30~* Deemed healthy to partake in the study at the discretion of the investigator~Exclusion Criteria~The presence of any of the following will preclude patient inclusion:~* Less than 18 years old~* BMI \>30~* On regular medication~* Known allergy to medications~* History of psychiatric, chronic cardiac / respiratory / renal disease~* Habitual smoker~* Screening heart rate of less than 60 beats per minute~* Screening heart rate of greater than 100 beats per minute~* Screening blood pressure of less than 100mmHg systolic and/or 55mmHg diastolic~* Any concomitant condition or circumstance that, at the discretion of the investigator, may affect the participant's ability to complete the study~* Current participation in another interventional research study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Placebo, Salbutamol, Nicardipine, Dobutamine) (Type: EXPERIMENTAL): Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)
- Group B (Placebo, Phenylephrine, Verapamil, Phentolamine) (Type: EXPERIMENTAL): Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues